Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Subscriptions

Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN

Alvar Agusti, Paul W. Jones, Eric Bateman, David Singh, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal 2011 38: p874; DOI:
Alvar Agusti
1Thorax Institute, Hospital Clínic and CIBER Enfermedades Respiratorias and Fundaciό Caubet-Cimera, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul W. Jones
2St George's, University of London, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Bateman
3Department of Pulmonology, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Singh
4Medicines Evaluation Unit, University of South Manchester, Manchester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Lamarca
5R&D Centre, Amirall, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gonzalo de Miquel
5R&D Centre, Amirall, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cynthia Caracta
6Clinical Development, Forest Research Institute, NJ, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esther Garcia Gil
5R&D Centre, Amirall, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction: The ATTAIN study investigated the efficacy and safety of two twice-daily doses of aclidinium bromide, a long-acting muscarinic antagonist, in patients with moderate to severe chronic obstructive pulmonary disease (COPD).

Methods: In this 24-week, double-blind trial, 828 patients were randomised (1:1:1) to twice-daily aclidinium (200 μg or 400 μg) or placebo. COPD symptoms were assessed using the Transitional Dyspnoea Index (TDI), patient-reported daily electronic diaries and Total Exact score. Reliever medication use was also assessed.

Results: Baseline characteristics were similar between the groups; FEV1% predicted 56.8±12.8%, focal BDI 6.8±2.1. More patients treated with aclidinium 200 μg or 400 μg had a clinically meaningful improvement in TDI focal score (≥1 unit) vs placebo at Week 24 (53.3% and 56.9% vs 45.5%; p=0.032 and 0.004, respectively). Aclidinium dose-dependently improved TDI focal score at Week 24, which was clinically meaningful for aclidinium 400 μg (1.0 unit) and statistically significant for both doses vs placebo (200 μg, p<0.05; 400 μg, p<0.001). Over the study period, aclidinium (both doses) was associated with a lower incidence of night-time (p<0.0001) and early-morning (p<0.01) COPD symptoms, a greater reduction in Total Exact score (p≤0.0001) and more days without reliever medication (p=0.0003) vs placebo.

Conclusions: Aclidinium 200 μg and 400 μg twice-daily provided statistically significant and clinically meaningful improvements in COPD symptoms in patients with moderate to severe COPD.

This study was supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc, New York, USA.

  • © 2011 ERS
Previous
Back to top
Vol 38 Issue Suppl 55 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN
Alvar Agusti, Paul W. Jones, Eric Bateman, David Singh, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal Sep 2011, 38 (Suppl 55) p874;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Improvement in symptoms and rescue medication use with aclidinium bromide in patients with chronic obstructive pulmonary disease: Results from ATTAIN
Alvar Agusti, Paul W. Jones, Eric Bateman, David Singh, Rosa Lamarca, Gonzalo de Miquel, Cynthia Caracta, Esther Garcia Gil
European Respiratory Journal Sep 2011, 38 (Suppl 55) p874;
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Fixed combination of glycopyrrolate and formoterol MDI (GFF-MDI) demonstrates superior inspiratory capacity (IC) compared to tiotropium DPI (Tio) following 7 days dosing, in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
  • Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
  • The ATTAIN study: Bronchodilatory effect of aclidinium bromide in chronic obstructive pulmonary disease (COPD)
Show more 96. Bronchodilators in asthma and COPD

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society